Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro

Journal of Bone and Mineral Research

Volumn 18, Issue 2, 2003, Pages 204-212

  Frith, Julie C ^a,b   Rogers, Michael J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Apoptosis; Bisphosphonate; Macrophage; Osteoclast; Prenylation

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; ALENDRONIC ACID; CLODRONIC ACID; IBANDRONIC ACID;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LABELING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; RABBIT;

ADENOSINE TRIPHOSPHATE; ALENDRONATE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE RESORPTION; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CELLS, CULTURED; CLODRONIC ACID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; MACROPHAGES; MICE; MICROSCOPY, FLUORESCENCE; OSTEOCLASTS; PINOCYTOSIS; RABBITS; TIME FACTORS;

EID: 0037302856     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.2.204     Document Type: Article

References (27)

1. Russell RGG, Rogers MJ 1999 Bisphosphonates: From the laboratory to the clinic and back again. Bone 25:97-106.
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC 2000 Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978.
3. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131-140.
4. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
5. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ 2001 The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201-2210.
6. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
7. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
8. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ 2001 Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465-473.
9. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA 1999 Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274:34967-34973.
10. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G 2000 Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241.
11. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S 1999 Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491-494.
12. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
13. Coxon FP, Helfrich MH, van't Hof RJ, Sebti SM, Ralston SH, Hamilton AD, Rogers MJ 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476.
14. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ 1997 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367.
15. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Monkkonen J 1997 Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B 704:187-195.
16. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ 1998 Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678.
17. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RGG 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11:1482-1491.
18. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ 2001 Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276:48213-48222.
19. Reszka AA, Halasy-Nagy J, Rodan GA 2001 Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59:193-202.
20. Wyllie AH, Kerr JF, Currie AR 1980 Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306.
21. Siris ES 1999 Goals of treatment for Paget's disease of bone. J Bone Miner Res 14:S2;49-52.
22. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS 2000 Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29:228-251.
23. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD 1999 Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 21:1025-1044.
24. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
25. Graham DY 1998 Excess gastric ulcers are associated with alendronate therapy. Am J Gastroenterol 93:1395-1396.
26. Rogers MJ, Xiong X, Ji X, Monkkonen J, Russell RG, Williamson MP, Ebetino FH, Watts DJ 1997 Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharmacol Res 14:625-630.
27. Endo Y, Shibazaki M, Yamaguchi K, Nakamura M, Kosugi H 1999 Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 126:903-910.